Literature DB >> 18266834

Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis.

Junko Nakazato1, Masaru Kishida, Rei Kuroiwa, Junko Fujiwara, Makiko Shimoda, Noriaki Shinomiya.   

Abstract

Atopic dermatitis (AD) is considered to be Th2 cell-mediated disorder. In most infants with AD, AD may be induced by food allergy. In the early stage of infantile AD, it is unclear whether there are changes in serum Th2 chemokines or in Th2 chemokine production by peripheral blood mononuclear cells (PBMC). Thirty-four patients with AD were examined (mean age, 4.5 months; female:male, 18:16). Ten age-matched infants with no history of allergic disease were used as controls. Thirty of these 34 patients were sensitized with ovalbumin (OVA; radioallergrosolvent score of >2). Serum levels of CCL17, CCL22, and CCL27 were measured with enzyme-linked immunosolvent assay (ELISA) kits and their correlation with the severity of skin lesions, defined by the scoring atopic dermatitis (SCORAD) index, was analyzed. The amounts of TNF-alpha, CCL17, CCL22, and CCL27 in the culture supernatants of PBMC from OVA-sensitized AD infants after stimulation with OVA were estimated with ELISA kits. Elevated serum CCL17, CCL22, and CCL27 levels significantly correlated with SCORAD index (r = 0.7181, p < 0.001; r = 0.5354, p < 0.005; r = 0.8312, p < 0.0001, respectively). CCL22 levels produced by PBMC from OVA-sensitized infants with AD reflected serum CCL22 levels. Only six of 30 OVA-sensitized patients in whom the skin signs increased immediately after OVA intake showed markedly high titers of TNF-alpha produced by PBMC after stimulation with OVA. These high TNF-alpha titers correlated significantly with serum CCL27 levels (r = 0.7181, p < 0.001). Serum concentrations of CCL17, CCL22, and CCL27 correlate well with the extent and intensity of AD in infants. Of the three Th2 chemokines examined, serum CCL27 correlated most significantly with the severity of AD. Thus, the peripheral immune responses of infantile AD patients are skewed to a Th2 dominant bias.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18266834     DOI: 10.1111/j.1399-3038.2007.00692.x

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  33 in total

1.  Therapeutic effects of recombinant Salmonella typhimurium harboring CCL22 miRNA on atopic dermatitis-like skin in mice.

Authors:  Won Suck Yoon; Seung Seok Lee; Yang Seok Chae; Yong Keun Park
Journal:  Exp Mol Med       Date:  2011-02-28       Impact factor: 8.718

2.  Ginsenoside Rg5:Rk1 attenuates TNF-α/IFN-γ-induced production of thymus- and activation-regulated chemokine (TARC/CCL17) and LPS-induced NO production via downregulation of NF-κB/p38 MAPK/STAT1 signaling in human keratinocytes and macrophages.

Authors:  Sungeun Ahn; Muhammad Hanif Siddiqi; Veronica Castro Aceituno; Shakina Yesmin Simu; Jinglou Zhang; Zuly Elizabeth Jimenez Perez; Yu-Jin Kim; Deok-Chun Yang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2015-12-29       Impact factor: 2.416

3.  Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques.

Authors:  Kimberly A Kraynyak; Michele A Kutzler; Neil J Cisper; Amir S Khan; Ruxandra Draghia-Akli; Niranjan Y Sardesal; Mark G Lewis; Jian Yan; David B Weiner
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

4.  Suppression of inflammation by recombinant Salmonella typhimurium harboring CCL22 microRNA.

Authors:  Won Suck Yoon; Seung Rel Ryu; Seung Seok Lee; Yang Seok Chae; Eun Jae Kim; Ji Hyun Choi; Sejin Oh; Se Ho Park; Ji Tae Choung; Young Yoo; Yong Keun Park
Journal:  DNA Cell Biol       Date:  2011-08-08       Impact factor: 3.311

5.  Lower serum levels of Th2-related chemokine CCL22 in women patients with multiple sclerosis: a comparison between patients and healthy women.

Authors:  A Jafarzadeh; H A Ebrahimi; S Bagherzadeh; F Zarkesh; F Iranmanesh; A Najafzadeh; A Khosravimashizi; M Nemati; A Sabahi; H Hajghani; H Daneshvar; M M Mohammadi
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092

6.  Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities.

Authors:  Mayte Suárez-Fariñas; Suzanne J Tintle; Avner Shemer; Andrea Chiricozzi; Kristine Nograles; Irma Cardinale; Shenghui Duan; Anne M Bowcock; James G Krueger; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2011-04       Impact factor: 10.793

7.  Are plasma IL-10 levels a useful marker of human clinical tolerance in peanut allergy?

Authors:  Larisa C Lotoski; F Estelle R Simons; Rishma Chooniedass; Joel Liem; Isha Ostopowich; Allan B Becker; Kent T HayGlass
Journal:  PLoS One       Date:  2010-06-17       Impact factor: 3.240

Review 8.  Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.

Authors:  Lawrence F Eichenfield; Wynnis L Tom; Sarah L Chamlin; Steven R Feldman; Jon M Hanifin; Eric L Simpson; Timothy G Berger; James N Bergman; David E Cohen; Kevin D Cooper; Kelly M Cordoro; Dawn M Davis; Alfons Krol; David J Margolis; Amy S Paller; Kathryn Schwarzenberger; Robert A Silverman; Hywel C Williams; Craig A Elmets; Julie Block; Christopher G Harrod; Wendy Smith Begolka; Robert Sidbury
Journal:  J Am Acad Dermatol       Date:  2013-11-27       Impact factor: 11.527

9.  CCR4 agonists CCL22 and CCL17 are elevated in pediatric OMS sera: rapid and selective down-regulation of CCL22 by ACTH or corticosteroids.

Authors:  Michael R Pranzatelli; Elizabeth D Tate; Nathan R McGee; Jerry A Colliver; Richard M Ransohoff
Journal:  J Clin Immunol       Date:  2013-01-23       Impact factor: 8.317

10.  The imbalance in serum concentration of Th-1- and Th-2-derived chemokines as one of the factors involved in pathogenesis of atopic dermatitis.

Authors:  Joanna Narbutt; Aleksandra Lesiak; Anna Sysa-Jedrzeiowska; Marcin Zakrzewski; Jarosław Bogaczewicz; Iwona Stelmach; Piotr Kuna
Journal:  Mediators Inflamm       Date:  2009-07-22       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.